Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

We have previously shown that the addition of the raltegravir/elvitegavir (RAL/EVG) primary resistance mutation N155H to the R263K dolutegravir (DTG) resistance mutation partially compensated for the fitness cost imposed by R263K while also slightly increasing DTG resistance in vitro (K. Anstett, T....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: Anstett, Kaitlin, Fusco, Robert, Cutillas, Vincent, Mesplède, Thibault, Wainberg, Mark A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2015
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4580168/
https://ncbi.nlm.nih.gov/pubmed/26246578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01725-15
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados